WO2007046123A3 - Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis - Google Patents

Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis Download PDF

Info

Publication number
WO2007046123A3
WO2007046123A3 PCT/IT2006/000737 IT2006000737W WO2007046123A3 WO 2007046123 A3 WO2007046123 A3 WO 2007046123A3 IT 2006000737 W IT2006000737 W IT 2006000737W WO 2007046123 A3 WO2007046123 A3 WO 2007046123A3
Authority
WO
WIPO (PCT)
Prior art keywords
taurine
osteoporosis
treatment
preventio
well
Prior art date
Application number
PCT/IT2006/000737
Other languages
French (fr)
Other versions
WO2007046123A2 (en
Inventor
Enrico Boldrini
Giulia Falcone
Original Assignee
Opocrin Spa
Enrico Boldrini
Giulia Falcone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opocrin Spa, Enrico Boldrini, Giulia Falcone filed Critical Opocrin Spa
Publication of WO2007046123A2 publication Critical patent/WO2007046123A2/en
Publication of WO2007046123A3 publication Critical patent/WO2007046123A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition for oral administration based on vitamins K and D, particularly indicated for the prevention and therapy of menopausal osteopenia and as a co-adjuvant in the treatment of osteoporosis, in which an enhanced absorption of vitamins K1 and D3 is obtained by combining these active ingredients with taurine, which promotes enteric absorption. The invention also concerns the use of a combination of vitamin K, vitamin D and taurine for the prevention and treatment of osteopenia and osteoporosis, particularly indicated in subjects with pathologies or disorders characterised by a reduced hepatic absorption.
PCT/IT2006/000737 2005-10-21 2006-10-16 Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis WO2007046123A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2005A000521 2005-10-21
IT000521A ITRM20050521A1 (en) 2005-10-21 2005-10-21 COMPOSITION BASED ON VITAMIN K AND D FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.

Publications (2)

Publication Number Publication Date
WO2007046123A2 WO2007046123A2 (en) 2007-04-26
WO2007046123A3 true WO2007046123A3 (en) 2007-11-22

Family

ID=37876811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2006/000737 WO2007046123A2 (en) 2005-10-21 2006-10-16 Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis

Country Status (2)

Country Link
IT (1) ITRM20050521A1 (en)
WO (1) WO2007046123A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589810A (en) 2008-06-03 2012-11-30 John Ray Biffin A method for increasing bone density and/or reducing any osteochondral defects in an equne or avian and a composition including vitamin k
DE202010012099U1 (en) 2010-09-02 2010-11-11 Hexal Ag Vitamin composition and dosage form comprising vitamin D3 suitable for osteoporosis prophylaxis and / or treatment
WO2016112553A1 (en) * 2015-01-17 2016-07-21 广州自远生物科技有限公司 Pharmaceutical composition for preventing and/or treating disease caused by coronavirus and/or rotavirus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129418A2 (en) * 1983-06-16 1984-12-27 Farley Health Products Limited Infant foods
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
WO2004019923A1 (en) * 2002-08-30 2004-03-11 Vitak Bv Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
WO2004026046A1 (en) * 2002-09-17 2004-04-01 Wyeth Infant formula containing partially hydrolyzed isolated soy protein with a reduced phytate content
WO2004080475A1 (en) * 2003-03-14 2004-09-23 Meiji Dairies Corporation Composition against infection with rotavirus and process for producing the same
WO2006028684A2 (en) * 2004-09-01 2006-03-16 Diversa Corporation Phytases, nucleic acids encoding them and methods of making and using them

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129418A2 (en) * 1983-06-16 1984-12-27 Farley Health Products Limited Infant foods
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
WO2004019923A1 (en) * 2002-08-30 2004-03-11 Vitak Bv Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
WO2004026046A1 (en) * 2002-09-17 2004-04-01 Wyeth Infant formula containing partially hydrolyzed isolated soy protein with a reduced phytate content
WO2004080475A1 (en) * 2003-03-14 2004-09-23 Meiji Dairies Corporation Composition against infection with rotavirus and process for producing the same
EP1623717A1 (en) * 2003-03-14 2006-02-08 Meiji Dairies Corporation Composition against infection with rotavirus and process for producing the same
WO2006028684A2 (en) * 2004-09-01 2006-03-16 Diversa Corporation Phytases, nucleic acids encoding them and methods of making and using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETROSIAN A M ET AL: "Taurine as a universal carrier of lipid soluble vitamins: a hypothesis.", AMINO ACIDS 2000, vol. 19, no. 2, 2000, pages 409 - 421, XP002453408, ISSN: 0939-4451 *

Also Published As

Publication number Publication date
ITRM20050521A1 (en) 2007-04-22
WO2007046123A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
IL154318A0 (en) Pharmaceutical compositions for the treatment of movement disorders
WO2006068697A3 (en) Compositions including iron
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
UY28931A1 (en) USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
TW200716208A (en) Modified and immediate release memantine bead formulation
EA200801275A1 (en) STABILIZED LANTAN CARBONATE COMPOSITIONS
MY143795A (en) Tetrahydropyridoindole derivatives
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
EA201001285A1 (en) APPLICATION OF 25-OH D3 FOR IMPACT ON HUMAN MUSCLE PHYSIOLOGY
WO2007142811A3 (en) Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
EP3318251A3 (en) Composition for preventing or treating obesity or lipid-related metabolic disease
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2009118726A3 (en) Oral combination of vitamins
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06810028

Country of ref document: EP

Kind code of ref document: A2